Genmab A/S (OTCMKTS:GNMSF) Announces Earnings Results

Genmab A/S (OTCMKTS:GNMSF) posted its quarterly earnings results on Tuesday. The company reported $0.55 earnings per share for the quarter, missing the consensus estimate of $3.10 by ($2.55), Zacks reports. The company had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.05 billion. Genmab A/S had a return on equity of 17.67% and a net margin of 25.89%.

Genmab A/S Price Performance

GNMSF traded down $12.85 during trading on Thursday, reaching $284.40. 9 shares of the stock were exchanged, compared to its average volume of 27. Genmab A/S has a twelve month low of $170.00 and a twelve month high of $352.00. The stock’s 50 day moving average price is $324.86 and its two-hundred day moving average price is $298.74.

About Genmab A/S

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.